Carissa Summa
Dermatology · Estero, FLNPI 1376614669
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,356 of the $2,740 with a category attached, or 86.0%. It is spread thinly across 19 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for dermatology clinicians in FL, where the typical reported total is $2,563.
Across 121 payments — averaging $22.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$534
- Organogenesis Inc.$401
- Lilly USA, LLC$372
- Pfizer$279
- AbbVie$186
- Novartis$185
- plus $784 from 13 others
What the payments were for
- Food & beverage$2,35686%
- Education$38414%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 25 | $534 |
| Organogenesis Inc. | 22 | $401 |
| Lilly USA, LLC | 14 | $372 |
| Pfizer | 9 | $279 |
| AbbVie | 10 | $186 |
| Novartis | 8 | $185 |
| Sun Pharmaceutical Industries Inc. | 4 | $154 |
| Sanofi | 5 | $137 |
| Galderma Laboratories, L.p. | 5 | $85 |
| Dermavant Sciences, Inc. | 3 | $81 |
| E.r. Squibb & Sons, L.L.C. | 3 | $63 |
| Arcutis Biotherapeutics, Inc. | 3 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Organon | 2 | $38 |
| Almirall LLC | 1 | $30 |
| Biofrontera Inc. | 2 | $28 |
| Incyte Corporation | 1 | $26 |
| Kerecis Limited | 1 | $22 |
| Merz North America, Inc. | 1 | $18 |
How this compares
$2,740 in reported general payments places this provider in the 50th percentile of 1,147 dermatology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VtamaTapinarof | 12 | $16,621 |
| Clobetasol Propionate | 94 | $4,147 |
| Fluorouracil | 50 | $3,147 |
| Fluocinonide | 89 | $2,785 |
| Triamcinolone Acetonide | 302 | $2,558 |
| Clindamycin Phosphate | 60 | $2,260 |
| Ketoconazole | 148 | $2,028 |
| Metronidazole | 33 | $1,471 |
| Gentamicin Sulfate | 26 | $863 |
| Ammonium Lactate | 38 | $666 |
| CiclopiroxCiclopirox Olamine | 37 | $648 |
| Doxycycline Hyclate | 30 | $600 |
| Nystatin | 46 | $547 |
| Mupirocin | 74 | $481 |
| Hydrocortisone | 81 | $415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dermavant Sciences, Inc.Vtama | $81 | $16,62112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,147 dermatology providers in Florida.
Other dermatology in Estero
- Robin GehrisEstero$583K
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- John MinniStuart$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
- Marc IngleseTallahassee$989K
- Jeremy GreenCoral Gables$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.